Metabolomics in serum of patients with non-advanced age-related macular degeneration reveals aberrations in the glutamine pathway.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
01
01
2019
accepted:
03
06
2019
entrez:
21
6
2019
pubmed:
21
6
2019
medline:
14
2
2020
Statut:
epublish
Résumé
Age-related macular degeneration (AMD) is a common, progressive multifactorial vision-threatening disease and many genetic and environmental risk factors have been identified. The risk of AMD is influenced by lifestyle and diet, which may be reflected by an altered metabolic profile. Therefore, measurements of metabolites could identify biomarkers for AMD, and could aid in identifying high-risk individuals. Hypothesis-free technologies such as metabolomics have a great potential to uncover biomarkers or pathways that contribute to disease pathophysiology. To date, only a limited number of metabolomic studies have been performed in AMD. Here, we aim to contribute to the discovery of novel biomarkers and metabolic pathways for AMD using a targeted metabolomics approach of 188 metabolites. This study focuses on non-advanced AMD, since there is a need for biomarkers for the early stages of disease before severe visual loss has occurred. Targeted metabolomics was performed in 72 patients with early or intermediate AMD and 72 control individuals, and metabolites predictive for AMD were identified by a sparse partial least squares discriminant analysis. In our cohort, we identified four metabolite variables that were most predictive for early and intermediate stages of AMD. Increased glutamine and phosphatidylcholine diacyl C28:1 levels were detected in non-advanced AMD cases compared to controls, while the rate of glutaminolysis and the glutamine to glutamate ratio were reduced in non-advanced AMD. The association of glutamine with non-advanced AMD corroborates a recent report demonstrating an elevated glutamine level in early AMD using a different metabolomics technique. In conclusion, this study indicates that metabolomics is a suitable method for the discovery of biomarker candidates for AMD. In the future, larger metabolomics studies could add to the discovery of novel biomarkers in yet unknown AMD pathways and expand our insights in AMD pathophysiology.
Identifiants
pubmed: 31220133
doi: 10.1371/journal.pone.0218457
pii: PONE-D-19-00025
pmc: PMC6586309
doi:
Substances chimiques
Biomarkers
0
Glutamine
0RH81L854J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0218457Déclaration de conflit d'intérêts
The commercial affiliation of S.F. to La Roche AG does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Prog Lipid Res. 2017 Apr;66:14-29
pubmed: 28104532
Neurochem Int. 2007 Nov-Dec;51(6-7):333-55
pubmed: 17517448
J Lipid Res. 2017 Sep;58(9):1785-1796
pubmed: 28698208
Ophthalmology. 2017 Dec;124(12):1753-1763
pubmed: 28712657
Prog Retin Eye Res. 2019 Mar;69:57-79
pubmed: 30423446
Nutrients. 2016 Oct 22;8(10):
pubmed: 27782072
Bull Exp Biol Med. 2007 Mar;143(3):320-2
pubmed: 18225752
PLoS One. 2014 Mar 07;9(3):e90973
pubmed: 24608419
Nutr Diabetes. 2016 Jul 18;6(7):e220
pubmed: 27428872
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
PLoS One. 2013 Aug 27;8(8):e72737
pubmed: 24015273
Dis Markers. 2013;35(5):281-6
pubmed: 24167375
PLoS One. 2017 May 18;12(5):e0177749
pubmed: 28542375
Surv Ophthalmol. 2018 Jan - Feb;63(1):9-39
pubmed: 28522341
Bioessays. 2004 Jul;26(7):778-85
pubmed: 15221859
Invest Ophthalmol Vis Sci. 2015 Dec;56(13):7766-73
pubmed: 26641553
BMC Ophthalmol. 2017 Sep 6;17(1):165
pubmed: 28874192
Ophthalmology. 2012 Feb;119(2):339-46
pubmed: 22133792
Eur J Pharm Sci. 2017 Nov 15;109S:S15-S21
pubmed: 28502671
Ophthalmology. 2017 Aug;124(8):1165-1174
pubmed: 28456421
Nat Genet. 2016 Feb;48(2):134-43
pubmed: 26691988
BMC Bioinformatics. 2011 Jun 22;12:253
pubmed: 21693065
Ophthalmology. 2018 Feb;125(2):245-254
pubmed: 28916333
PLoS One. 2015 Aug 14;10(8):e0135437
pubmed: 26274920
Biochim Biophys Acta. 2012 May;1821(5):754-61
pubmed: 21979151
Autoimmune Dis. 2014;2014:532487
pubmed: 24876950
Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO88-BIO98
pubmed: 28525563
Crit Rev Biomed Eng. 2013;41(3):205-21
pubmed: 24579644
Lancet. 2018 Sep 29;392(10153):1147-1159
pubmed: 30303083
Eur J Pharmacol. 2016 Sep 15;787:78-83
pubmed: 26948315
FASEB J. 2014 Dec;28(12):5163-71
pubmed: 25169057
Invest Ophthalmol Vis Sci. 2014 Jan 09;55(1):210-4
pubmed: 24235017
Int J Mol Sci. 2012;13(8):10041-66
pubmed: 22949847
Amino Acids. 1999;17(3):227-41
pubmed: 10582122
BMC Ophthalmol. 2010 Dec 13;10:31
pubmed: 21144031
JAMA Ophthalmol. 2018 May 1;136(5):473-481
pubmed: 29596588
Ophthalmology. 2019 Mar;126(3):393-406
pubmed: 30315903